FDA’s Psychedelic Guidance; Mass Shootings and Car Crashes; ADHD Drug Misuse Down

The FDA finalized clinical guidance for psychedelic drug developers and scheduled a public hearing for September to discuss potential therapeutic uses.

Meanwhile, HHS and the VA are partnering to speed up the research and development of rapid-acting psychedelic treatments for veterans with severe mental health conditions.

People with schizophrenia and bipolar I disorder had improvements in clinical symptoms and cognitive function after 4 months on a ketogenic diet, a randomized trial showed. (Schizophrenia Bulletin)

A systematic review and meta-analysis consistently linked loss of smell with a higher risk of depressive symptoms. (JAMA Otolaryngology-Head & Neck Surgery)

Continuing selective serotonin reuptake inhibitors during pregnancy was not associated with congenital anomalies or infant ICU stays in a cohort study, but it was linked to delayed neonatal adaptation. (JAMA Network Open)

Mass shootings were tied to a temporary nationwide increase in fatal motor vehicle crashes the next day, a quasi-experimental analysis found. (JAMA Psychiatry)

Generative artificial intelligence is ready for clinical psychopharmacology, but only as a heavily supervised assistant handling lower-risk tasks, according to one psychiatrist. (Journal of Clinical Psychiatry)

Researchers found a correlation between excessive phone use in parents and insecure attachment styles in children. (Frontiers in Psychology)

Meta, the parent company of Facebook and Instagram, appealed the landmark jury verdict that found the platforms to blame for social media addiction in young users. (AP)

After missing a self-imposed May deadline for deciding whether to ban electric shock devices, the FDA quietly announced it would make a decision by November.

Attention deficit-hyperactivity disorder (ADHD) stimulant misuse plunged from 7.8% in 2022 to 3.7% in 2023, a drop researchers said may have been driven by the ongoing shortage of immediate-release medications. (Journal of Clinical Psychopharmacology)

A federal appeals court revived hundreds of lawsuits against acetaminophen (Tylenol) maker Kenvue, claiming that the use of the painkiller in pregnancy can cause autism or ADHD in offspring. (Reuters via AOL)

A 32-year-old woman detailed her experience navigating an involuntary mental health hold, exposing the critical shortage of psychiatric hospital beds in the U.S. (KFF Health News)

Hospitalization for an infection was associated with a higher rate of psychiatric and neurological diagnoses over the subsequent 2 years, cohort data suggested. (JAMA Psychiatry)

The FDA granted 510(k) clearance to Universal Brain’s device that measures brain function using EEG and event-related potentials.

Please enable JavaScript to view the comments powered by Disqus.